S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:MCRB

Seres Therapeutics Stock Forecast, Price & News

$10.68
-0.75 (-6.56%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$10.54
$11.69
50-Day Range
$6.02
$11.43
52-Week Range
$5.41
$29.90
Volume
2.52 million shs
Average Volume
2.43 million shs
Market Capitalization
$980.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.54
30 days | 90 days | 365 days | Advanced Chart
Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Seres Therapeutics logo

About Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Headlines

First Week of MCRB April 2022 Options Trading
December 3, 2021 |  nasdaq.com
Seres Therapeutics (NASDAQ:MCRB) Trading Up 4.2%
November 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
155
Year Founded
N/A

Sales & Book Value

Annual Sales
$33.22 million
Book Value
$1.91 per share

Profitability

Net Income
$-89.13 million
Pretax Margin
-21.79%

Debt

Price-To-Earnings

Miscellaneous

Free Float
89,092,000
Market Cap
$980.96 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/01/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

662nd out of 1,390 stocks

Pharmaceutical Preparations Industry

307th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics
or view top-rated stocks.

How has Seres Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MCRB stock has increased by 304.5% and is now trading at $10.68.
View which stocks have been most impacted by COVID-19
.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Seres Therapeutics
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) released its earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.47) by $1.19. Seres Therapeutics had a negative net margin of 21.79% and a negative trailing twelve-month return on equity of 22.73%. During the same period in the previous year, the firm posted ($0.36) EPS.
View Seres Therapeutics' earnings history
.

What price target have analysts set for MCRB?

7 brokerages have issued 12 month price objectives for Seres Therapeutics' stock. Their forecasts range from $7.00 to $32.00. On average, they expect Seres Therapeutics' stock price to reach $20.83 in the next year. This suggests a possible upside of 95.1% from the stock's current price.
View analysts' price targets for Seres Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:
  • Eric D. Shaff, President, Chief Executive Officer & Director
  • Marcus Chapman, Senior Vice President-Operations
  • David A. Arkowitz, EVP, Chief Financial & Accounting Officer
  • Matthew R. Henn, Chief Scientific Officer & Executive VP
  • Barbara McGovern, Vice President-Medical Affairs

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), Janus Henderson Group PLC (4.72%), Two Sigma Investments LP (1.09%), Geode Capital Management LLC (1.04%), Sumitomo Mitsui Trust Holdings Inc. (0.95%) and Nikko Asset Management Americas Inc. (0.95%).
View institutional ownership trends for Seres Therapeutics
.

Which major investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Goldman Sachs Group Inc., Geode Capital Management LLC, Millennium Management LLC, Principal Financial Group Inc., and LPL Financial LLC.
View insider buying and selling activity for Seres Therapeutics
or view top insider-selling stocks.

Which major investors are buying Seres Therapeutics stock?

MCRB stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Voloridge Investment Management LLC, Janus Henderson Group PLC, SG Americas Securities LLC, Two Sigma Advisers LP, Lion Point Capital LP, Hudson Bay Capital Management LP, and UBS Group AG.
View insider buying and selling activity for Seres Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $10.68.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $980.96 million and generates $33.22 million in revenue each year. The biotechnology company earns $-89.13 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 155 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.